Inventor

Milind Rajopadhye

Inventor

Westford, MA, US

Overview

1998–2019

Patent span

Chemistry

Primary field (CPC C)

Patents· 43 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes31%

C07DHeterocyclic compounds21%

C07KPeptides16%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations9%

C09BOrganic dyes or closely-related compounds for producing dyes, e.g. pigments8%

G01NInvestigating or analysing materials by determining their chemical or physical properties4%

C07BGeneral methods of organic chemistry3%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%

B82YSpecific uses or applications of nanostructures2%

A61BDiagnosis1%

PatentTitleYear

10,442,930Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels2019 10,092,188Methods and compositions for identifying subjects at risk of developing stent thrombosis2018 9,999,687Fluorescent imaging agents2018 9,913,917'Biocompatible fluorescent metal oxide nanoparticles'2018 9,694,089'Integrin targeting agents and in-vivo and in-vitro imaging methods using the same'2017 9,574,085'Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels'2017 9,427,481'Fluorescent imaging agents'2016 8,864,821'Methods and compositions for identifying subjects at risk of developing stent thrombosis'2014 8,815,214'Fluorescent imaging agents'2014 8,771,646'Nicotinic acid and picolinic acid derived near-infrared fluorophores'2014 8,685,370'Integrin targeting agents and in-vivo and in-vitro imaging methods using the same'2014 8,455,651'Nicotinic acid and picolinic acid derived near-infrared fluorophores'2013 8,173,819'Nicotinic and picolinic acid derived near-infrared fluorophores'2012 7,947,256'Biocompatible fluorescent imaging agents'2011 7,332,149'Vitronectin receptor antagonist pharmaceuticals'2008 7,321,045'Vitronectin receptor antagonist pharmaceuticals'2008 7,090,828'Vitronectin receptor antagonist pharmaceuticals'2006 7,060,248'Matrix metalloproteinase inhibitors'2006 7,052,673'Pharmaceuticals for the imaging of angiogenic disorders'2006 7,018,611'Vitronectin receptor antagonist pharmaceuticals'2006 6,989,139'Matrix metalloproteinase inhibitors'2006 6,818,659'(2S)-2-amino-4-(2-amino-(3,4,5,6-tetrahydropyrimidin-4-yl) butanoyl and its use in cyclic and acyclic peptides'2004 6,818,201'Vitronectin receptor antagonist pharmaceuticals'2004 6,800,273'Pharmaceuticals for the imaging of angiogenic disorders'2004 6,794,518'Vitronectin receptor antagonist pharmaceuticals'2004 6,743,412'Vitronectin receptor antagonist pharmaceuticals'2004 6,689,337'Vitronectin receptor antagonist pharmaceuticals'2004 6,683,163'Vitronectin receptor antagonist pharmaceuticals'2004 6,656,448'Matrix metalloproteinase inhibitors'2003 6,569,402'Vitronectin receptor antagonist pharmaceuticals'2003 6,558,649'Vitronectin receptor antagonist pharmaceuticals'2003 6,537,520'Pharmaceuticals for the imaging of angiogenic disorders'2003 6,524,554'Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer'2003 6,511,648'Vitronectin receptor antagonist pharmaceuticals'2003 6,511,649'Vitronectin receptor antagonist pharmaceuticals'2003 6,416,733'Radiopharmaceuticals for imaging infection and inflammation'2002 6,322,770'Indazole vitronectin receptor antagonist pharmaceuticals'2001 6,022,523'Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders'2000 6,015,904'Stable reagents for the preparation of radio pharmaceuticals'2000 5,961,952'.sup.99m Tc-tertiary-butyl isonitrile as breast tumor imaging agents'1999 5,888,970'Technetium-99m labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents'1999 5,879,657'Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders'1999 5,750,088'Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–2019Based in Westford, MA, US· patent location history

1999–2001Patents assigned to DU PONT PHARM CO (4)· patent assignee history

2002–2008Patents assigned to BRISTOL MYERS SQUIBB PHARMA CO (20)· patent assignee history

2011–2019Patents assigned to VISEN MEDICAL INC (14)· patent assignee history

2012–2018Patents assigned to RAJOPADHYE MILIND (7)· patent assignee history

2014–2018Patents assigned to GROVES KEVIN (3)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
BRISTOL MYERS SQUIBB PHARMA CO	20	2002–2008
VISEN MEDICAL INC	14	2011–2019
RAJOPADHYE MILINDself	7	2012–2018
DU PONT PHARM CO	4	1999–2001
GROVES KEVIN	3	2014–2018

Locations

Location	Patents	Span
Westford, Massachusetts, US	43	1998–2019